Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2011

View Archived Issues

Archaeosome-encapsulated RD T-cell antigen vaccine efficacious against experimental tuberculosis

Herceptin conjugates induce programmed necrotic tumor cell death

Diamyd to concentrate resources on pain portfolio

Eisai enrolls participants in phase III rufinamide study

Cytos Biotechnology to focus on lead product

Verona Pharma reports data from phase II RPL-554 trial

Emergent BioSolutions begins trial of TRU-016 in relapsed, indolent lymphoma

Allos Therapeutics begins phase III registration trial of Folotyn

First Ultragenyx product enters clinical development

New GPR52 receptor agonists prepared by Takeda

Researchers at Pfizer disclose new gamma-secretase modulators

Lexicon Pharmaceuticals reports phase II data on telotristat etiprate

Nippon Chemiphar presents new GPR119 receptor agonists

Scientists at Vertex design novel PKC-theta inhibitors

Sanofi synthesizes novel fatty-acid amide hydrolase 1 inhibitors

New prodrugs of proteasome inhibitors designed by Cephalon

Roche obtains FDA approval for melanoma drug and companion diagnostic

FDA approves Intersect ENT's Propel implant

Gentium withdraws defibrotide NDA

Dual FGF/VEGF pathway inhibitor shows promise in limiting tumor resistance to VEGF inhibition

FDA accepts for review Protalix Biotherapeutics' resubmitted NDA for taliglucerase alfa

New approval for Progensa PCA3 test

Zogenix's phase III trial of Zohydro meets primary endpoint

Paladin Labs to acquire Labopharm

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...